U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 21

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated **August 1, 2013,**
1. St. Mary Medical Center - Hobart	3. License number 13-03459-03 is amended in its entirety to read as follows:
2. 1500 South Lake Park Avenue Hobart, Indiana 46342	4. Expiration date September 30, 2015
	5. Docket No. 030-31379 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 0.5 curies
D. Cesium-137 permitted by 10 CFR 35.400	D. Sealed sources (3M Model 6500 Series and 6520; IPL Model 67-800 Series and 67-820 Series)	D. One curie
E. Iodine-125 permitted by 10 CFR 35.400	E. Sealed sources (Best Medical International 2300 Series; 3M Model Nos. 6711 and 6702; Theragenics Corp. Model No. I25.S06; IsoAid Model Advantage IAI-125A; Draximage LLC Model LS-1; Implant Sciences Corp. Model 3500; North American Scientific Model 3631; Bard Brachytherapy, Inc. Model STM – 1251; Bebig Trade, Inc. Model I25.S06; Medi-Physics, Inc. Model 6733 EchoSeed)	E. 500 millicuries

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-03459-03
Docket or Reference Number
030-31379

Amendment No. 21

F. Palladium-103 permitted by 10 CFR 35.400	F. Sealed sources (Best Medical International 2300 Series; Theragenics Corp. Model No. 200; IsoAid Model Advantage IAPd-103A; North American Scientific Model 3633; International Brachytherapy, Inc. Model 1032p OptiSeed)	F. 500 millicuries
G. Cesium-131 permitted by 10 CFR 35.400	G. Sealed sources (Best Medical International 2300 Series and IsoRay, Inc. Model CS-1)	G. 500 millicuries
H. Samarium-145 permitted by 10 CFR 35.400	H. Sealed sources (Best Medical International 2300 Series)	H. 500 millicuries
I. Iridium-192 permitted by 10 CFR 35.400	I. Sealed sources (Best Medical International Model 81-01 Series)	I. One curie
J. Any byproduct material permitted by 10 CFR 31.11	J .Prepackaged Kits	J. 3 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. through I., inclusive: Any manual brachytherapy procedure permitted by 10 CFR 35.400.

J. In vitro studies.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 1500 South Lake Park Avenue, Hobart, Indiana.

11. The Radiation Safety Officer for this license is James C. Hatten.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-03459-03
Docket or Reference Number
030-31379

Amendment No. 21

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Jong-Yuan Kuo, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Mikhail Jeha, M.D.	10 CFR 35.100 and 35.200.
Jesse Reyes, M.D.	10 CFR 35.100 and 35.200.
Koppolu P. Sarma, M.D.	10 CFR 35.300 (for palliative treatment of bone pain using strontium-89) and 35.400.
Kamala Modur, M.D.	10 CFR 35.400.
Erlinda Roque-Kerekas, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Jeffrey Jon Quackenbush, M.D.	10 CFR 35.300 and 35.400.
Shawn R. Kenney, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
Jonathon T. Lee, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
Francis X. Roche, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Thomas M. Hoess, M.D.	10 CFR 35.100, 35.200, 35.500, and 31.11.
Vijah P. Shah, M.D.	10 CFR 35.100 and 35.200.
Harish Shah, M.D.	10 CFR 35.100 and 35.200.
Kais J. Yehyawi, M.D.	10 CFR 35.100 and 35.200.
Abdul Kawamleh, M.D.	10 CFR 35.100 and 35.200.

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-03459-03
Docket or Reference Number
030-31379

Amendment No. 21

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee=s ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated July 19, 2005; and,

B. Letters dated October 9, 2006, November 9, 2006, January 2, 2009, January 18, 2010, March 8, 2010, January 22, 2013, (with attachment), March 18, 2013 (pertaining to RSO change), March 18, 2013, (limited to phase I approval for renovations, release of nuclear medicine department for unrestricted use and addition of renovated spaces), June 7, 2013 (with attachments), July 8, 2013 (with attachments) and **August 1, 2013**.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 2 0 2013

By Toye L. Simmons

Toye L. Simmons
Materials Licensing Branch
Region III